Tectonic - TECX Company Value to Revenue

Tectonic Therapeutic Inc. (TECX) - corporate logo

The financial performance of Tectonic Therapeutic, Inc. (TECX) depends on the success of G protein-coupled receptor trials and the inflow of R&D capital. The EV/Sales multiple trajectory visualizes the trend's stability, where 0.00 serves as the current metric level. High bioengineering costs and FDA patents create significant barriers to entry. The environmental profile is limited by strict adherence to laboratory biosafety during protein synthesis.

TECX (Tectonic) Enterprise Value-to-Revenue Ratio history from 11/23/2025 to 11/20/2026

Tectonic Therapeutic Inc. - analytical breakdowns and key metrics (TECX)

- cash and cash flow indicators:
Fundamental company valuation:Tectonic Therapeutic, Inc.
Finished products of Tectonic Therapeutic

The development of Tectonic Therapeutic, Inc. (TECX) depends on the successful creation of protein-based drugs and the protection of intellectual property. The effectiveness of these developments directly impacts market capitalization and, consequently, the calculated multiple. This metric measures the total enterprise value, including debt minus cash, relative to sales volume. This allows for an assessment of the asset's fundamental value regardless of financial leverage. The EV/Sales trend for Tectonic Therapeutic, Inc. (TECX) reflects real market demand for the technology.

Direct competitors

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio